We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $159M
1-Year Est. Return 60.94%
This Fund
S&P 500
This Quarter Est. Return
+11.81%
1 Year Est. Return
+60.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$82.4M
AUM Growth
-$3.68M
Cap. Flow
-$4.59M
Cap. Flow %
-5.57%
Top 10 Hldgs %
97.53%
Holding
20
New
2
Increased
5
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ACHV icon
Achieve Life Sciences
ACHV
+$10.5M
2
ABEO icon
Abeona Therapeutics
ABEO
+$1.99M
3
CAPR icon
Capricor Therapeutics
CAPR
+$739K
4
DCTH icon
Delcath Systems
DCTH
+$676K
5
MIST icon
Milestone Pharmaceuticals
MIST
+$453K

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$9.95M
2
RNAM
Avidity Biosciences
RNAM
+$5.27M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.25M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$1.17M
5
CMPX icon
Compass Therapeutics
CMPX
+$434K

Sector Composition

Rank Sector Weight
1 Healthcare 69.43%
2 Energy 30.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PAGP icon
1
Plains GP Holdings
PAGP
$5.23B
$24.7M 30.01%
1,272,360
– –
ACHV icon
2
Achieve Life Sciences
ACHV
$626M
$13.9M 16.88%
6,153,091
+3,699,999
+151% +$10.5M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$12.2M 14.82%
228,884
– –
PHAT icon
4
Phathom Pharmaceuticals
PHAT
$912M
$8.85M 10.74%
922,927
-212,000
-19% -$1.17M
ABEO icon
5
Abeona Therapeutics
ABEO
$345M
$5.53M 6.71%
974,022
+350,000
+56% +$1.99M
APLT
6
DELISTED
Applied Therapeutics
APLT
$3.51M 4.26%
11,285,420
– –
MIST icon
7
Milestone Pharmaceuticals
MIST
$144M
$3.48M 4.22%
1,791,557
+340,000
+23% +$453K
DCTH icon
8
Delcath Systems
DCTH
$422M
$3.07M 3.73%
226,052
+48,452
+27% +$676K
TCRX icon
9
TScan Therapeutics
TCRX
$51.9M
$3.03M 3.67%
2,087,139
– –
ZVRA icon
10
Zevra Therapeutics
ZVRA
$563M
$2.04M 2.48%
231,874
+52,000
+29% +$422K
CAPR icon
11
Capricor Therapeutics
CAPR
$1.14B
$695K 0.84%
+70,000
New +$739K
LONA
12
LeonaBio Inc
LONA
$69.4M
$451K 0.55%
149,279
– –
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$423K 0.51%
146,381
– –
CMPX icon
14
Compass Therapeutics
CMPX
$373M
– –
-228,317
Closed -$434K
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-30,032
Closed -$9.95M
RNAM
16
DELISTED
Avidity Biosciences
RNAM
– –
-178,500
Closed -$5.27M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-183,259
Closed -$2.25M

Similar funds

OS
Objectivity Squared Charleston, South Carolina $159M AUM 22.15% 1-Year Est. Return
BDAM
Blue Door Asset Management Stamford, Connecticut $159M AUM 38.2% 1-Year Est. Return
OC
Oppenheimer & Close New York $159M AUM 60.56% 1-Year Est. Return
JF
Jericho Financial Westerville, Ohio $159M AUM 27.21% 1-Year Est. Return
1L
10Elms LLP Tulsa, Oklahoma $159M AUM 13.16% 1-Year Est. Return
USWIA
UP Strategic Wealth Investment Advisors Pittsburgh, Pennsylvania $159M AUM 24.31% 1-Year Est. Return
EWA
Elevate Wealth Advisory Athens, Georgia $158M AUM 15.64% 1-Year Est. Return
RP
RIHO Partners Tucson, Arizona $159M AUM

Propel Bio Management's Q2 2025 Portfolio in Review

As of Q2 2025, Propel Bio Management held 20 positions worth $82.4M, down 4.3% from $86.1M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Propel Bio Management withdrew a net $4.59M in Q2 2025, closing 4 positions and reducing 2 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $9.95M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 67% a quarter earlier, followed by Energy.

Against the trend, Propel Bio Management opened a new position in Capricor Therapeutics worth $695K.

  • Propel Bio Management's largest Q2 2025 buy was Capricor Therapeutics: 70,000 shares worth $695K.
  • Propel Bio Management added most to Achieve Life Sciences in Q2 2025, an estimated $10.5M increase.
  • Propel Bio Management's biggest Q2 2025 reduction was Phathom Pharmaceuticals, cutting an estimated $1.17M.
  • Propel Bio Management fully exited Madrigal Pharmaceuticals in Q2 2025, selling an estimated $9.95M.
  • Propel Bio Management's ten largest holdings make up 98% of its $82.4M portfolio in Q2 2025.
  • Propel Bio Management opened 2 new positions and closed 4 in Q2 2025.
  • Propel Bio Management's portfolio value fell 4.3% quarter-over-quarter to $82.4M.

Based on Propel Bio Management's 13F filing for Q2 2025, filed 13 Aug 2025.